TG Therapeutics, Inc. (TGTX)
POSITIVEFundamental
63
मूल्य
$55.94
मार्केट कैप
$8.21B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
बैलेंस शीट और तरलता
राजस्व
$800M
पिछले 12 महीने (30/6/2026 तक)
शुद्ध आय
$441M
पिछले 12 महीने (30/6/2026 तक)
Free Cash Flow
$-25M
कुल इक्विटी
$648M
कुल देनदारियाँ
$415M
Current Ratio
4.27
Interest Coverage
3.64
Debt/EBITDA
6.11
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$53.81
वर्तमान मूल्य
$55.94
Margin of Safety
-4.0%
Fair Value सीमा
$36.39 - $71.24
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
20.44
ROE
69.0%
P/B Ratio
14.19
P/FCF
493.15
Gross Margin
82.4%
ROIC
7.8%
लाभप्रदता Radar
Value Creation (Economic Moat)
ROIC
7.8%
WACC
13.3%
ROIC − WACC
-5.5 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental विश्लेषण मानदंड
पास (16)
- EPS shows upward trend
- Price CAGR 27.86%
- ROIC 7.9%
- Gross Margin 82.4%
- Debt/Equity ratio
- Operating Margin 17.1%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 72.3%
- Revenue Growth 5Y 426.7%
- Analyst Consensus 86% Buy
- Net Margin Trend 55.2% vs 13.3%
फेल (9)
- P/FCF 493.15
- P/B Ratio 14.19
- Debt/EBITDA
- Price below Graham Number
- DCF valuation (Unknown)
- Earnings Surprise avg -53.8%
- Earnings Quality (OCF/NI) 0.04
- Share Dilution 3.6%
- Piotroski F-Score 4/9
अनुपलब्ध (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
मिश्रित संकेत: कुछ क्षेत्रों पर ध्यान देना आवश्यक
Earnings गुणवत्ता
निम्न गुणवत्ता: accounting की जांच करें
शेयर Dilution
नए शेयर जारी कर रही है, स्वामित्व को कम कर रही है
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Michael S. Weiss Esq., J.D. | Chairman, CEO & President | 59 |
| Mr. Sean A. Power CPA | CFO, Corporate Secretary & Treasurer | 43 |
| Ms. Jenna Bosco | Senior Vice President of Corporate Communications | - |
| Mr. Adam Waldman | Chief Commercialization Officer | - |
Audit जोखिम
9
बोर्ड जोखिम
10
मुआवजा जोखिम
10
शेयरधारक अधिकार जोखिम
3
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for TGTX, sourced from Markets Gazette.
- 6/18/2026POSITIVETG Therapeutics Stock Rises Thursday: What's Driving The Gains?
TG Therapeutics Inc. experienced a notable stock increase on Thursday, fueled by positive investor sentiment surrounding recent clinical trial updates for its drug BRIUMVI. The ongoing positive reception to these developments suggests that the market is factoring in potential future revenue streams and market share gains for BRIUMVI. This sustained upward momentum indicates strong confidence in the company's drug development pipeline and its commercial prospects, potentially leading to further analyst upgrades and increased institutional interest.
- 2/26/2026NEUTRALTG Therapeutics (TGTX) Q4 2025 Earnings Transcript
TG Therapeutics (TGTX) has released the transcript of its Q4 2025 earnings conference call. While the document is now available, specific financial figures, future outlook, and management commentary have not been disclosed or are currently inaccessible. Investors are keenly awaiting a detailed analysis of this information to assess the company's performance during the period and its projections for the upcoming fiscal year. The lack of concrete data prevents an immediate evaluation of the stock's impact, keeping market sentiment on hold pending further clarification.
via Markets Gazette